Asparaginase, first shown to have anti-tumor properties in the 1960's (2), is the most recent chemotherapeutic to become universally incorporated into the multi-agent backbone in the treatment of ALL. This evidence concerns the gene ASPG and acute lymphoblastic leukemia.